Hyperparathyroidism with or without adenoma has occasionally been reported in association with lithium treatment, and in symptomatic patients depression, psychosis and an exacerbation of existing psychopathology may occur. Three lithium-treated patients with hyperparathyroidism are reported, in whom discontinuation of lithium in one and removal of parathyroid adenomata in two led to both a reduction in plasma calcium levels and an improvement in their psychopathology.
Introduction
Chronic administration of lithium has been reported to cause hypercalciuria. In animal pharmacological experiments, lithium increased gut absorption of calcium leading to calciuria (Lau et al. 1978) . Brown (1981) has shown that lithium induces abnormal calciumregulated parathormone (PTH) release in dispersed bovine parathyroid cells, indicating that hyperparathyroidism may simply be related to this abnormal PTH response. Supporting the findings of Brown (1981) were the results of Christensson (1976) and Christiansen et al. (1978) which revealed significant elevations (P < 0.001) of serum calcium, magnesium and immunoreactive PTH in 96 patients on long-term lithium; such an increase may be a dysregulation in parathyroid secretion (Christiansen et al. 1976 ). Shen & Sherrard (1982) proved that parathyroid glands retained their responsiveness after lithium administration, but that a higher level of calcium was required to inhibit PTH secretion, a phenomenon known as a reset of the 'set point' or 'calcistat' (Murray et al. 1972) . Franks et al. (1982) found that an increase in calcium after lithium therapy was benign, and even recommended against routinely estimating blood calcium levels; whilst Carman & Wyatt (1979) stated that an increase in calcium within 24 hours after lithium therapy is a favourable prognostic indicator.
Fourteen cases (11 women, 3 men) of hyperparathyroidism associated with lithium therapy have been reported in the literature (Table 1) . Their ages ranged between 33 and 70 years, with a mean of 51.3 years. The majority were women. An associated parathyroid adenoma was noted in 9 patients. In all cases, both the psychiatric and laboratory findings improved only after the adenomas were surgically removed. In one patient lithium was reinstituted after the operation to control the recurrence of manic symptoms (Graze 1981) . While most patients developed hyperparathyroidism after several years of lithium therapy, an increase in serum calcium from the first day of lithium treatment and hyperparathyroidism as early as one month after lithium have been reported (Rothman 1982 , Shen & Sherrard 1982 .
Another important aspect is that the thyroid and parathyroid are embryologically and anatomically closely related. Thirty-three cases of hyperthyroidism with parathyroid hypersecretion have been reported (Richards 1970) . Similarly, it has been noted that 20% of hyperparathyroid cases had concomitant thyroid abnormalities (Goldsmith et al. 1971 ). Garfinkel et al. (1973) reported an associated hypothyroidism during lithium therapy, while MacGregor (1977) found an associated hyperthyroidism and hyperparathyroidism. 'Accepted 5 July 1983 0141-0768/83/121026-04/$01.00
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We now report 3 lithium-treated patients with hyperparathyroidism, 2 of whom had parathyroid adenomata.
Case reports
Case 1: A 30-year-old married woman was admitted to St Mary's Hospital, Montreal, in May 1972 with a first episode of acute mania and was treated with lithium carbonate (LiCO3) 300 mg three times daily. All her laboratory investigations as well as ECG were normal prior to the initiation of lithium treatment. After two weeks of lithium treatment she developed left-sided Bell's palsy of lower motor neuron type. She was discharged as improved after 5 weeks. Her mood remained normal and stable until 1978. At that time, a routine examination revealed mild hypertension (180/100 mmHg) and laboratory investigations revealed a plasma calcium level of 11.8 mg/l00 ml, sodium 138 mmol/l, potassium 3.9 mmol/l, haematocrit 35%, BUN 18, and total plasma proteins of 7.1. A diagnosis of hyperparathyroidism was made and the lithium was discontinued to consider use of diuretics. Four weeks later her plasma calcium level was normal and had remained so at investigation in November 1982.
Case 2: A 45-year-old woman, with a past history of 10 or more episodes of mania and .depression, was treated for mania with LiCO3 as an outpatient. Her manic symptoms responded well to this'treatment. However, depressive episodes continued to recur with attenuated severity, and intermittent antidepressant therapy along with lithium kept her functional. In 1974, she was brought. to the emergency unit with acute depression and severe psychomotor retardation. As the patient was seriously ill and the psychopathology was different from that in the past, she was admitted. Medical investigation revealed no abnormality. Imipramine 225 mg daily for three weeks did not produce any change in her psychopathology. She responded minimally to electroconvulsive therapy given thrice weekly for two weeks. The patient was discharged at the request of her husband.
A week later she was readmitted becaus'e of muscular incoordination, vacant gaze, confusion, disorientation and incontinence of urine and faeces. Physical examination revealed slight tenderness over the thyroid gland region. LiCO3 was withheld as lithium toxicity was suspected. Laboratory investigations revealed a plasma calcium of 13.8 mg/100 ml, sodium 140 mmol/l, chloride 115 mmol/l, BUN 18, haematocrit 30% and total plasma proteins of 7.9. Serum lithium was 0.5 mEq/l. Her T3 (160 mg/dl) and T4 (8 pg/dl) were also normal. On the basis of these findings, a diagnosis of primary hyperparathyroidism was made. Surgical exploration revealed a parathyroid adenoma, the removal of which was followed by a rapid remission of her psychopathology.
Case 3: A 37-year-old black woman was hospitalized at Harbor-UCLA Medical Center in August 1980. There had been one prior hospital admission in 1977. On admission, elation, insomnia, aggressive and assaultive behaviour, delusion that she was on a special mission from God and pressured speech were noted. She was diagnosed as having a bipolar affective disorder with mania and was treated with 1800 mg LiCO3 daily. She responded well and was discharged with a blood lithium level of 0.7 mEq/l. In October 1980 she was readmitted with similar symptoms consequent to discontinuation of lithium. She was started on 1200 mg LiCO3 per day and by 7 October had a blood lithium level of 0.8 mEq/l, but with no diminution of her symptoms. Seven days later, on 1800 mg LiCO3 daily, some improvement was noted. However, her blood lithium level remained at 0.7 mEq/l, and therefore on 21 October LiCO3 was increased to 2100 mg per day. Two days later she became excessively sedated, with nausea and vomiting; her plasma lithium level was 2.5 mEq/l. Lithium was stopped and the patient transferred to a medical ward for 36 hours, subsequently being restarted on LiCO3 1200 mg/day. Following this, she became increasingly confused, disorganized, and assaultive. Lithium was discontinued (serum level 1.2 mEc/l). However, she continued to deteriorate, becoming disoriented and stuporous. At this time, investigations revealed a plasma calcium level of 15.8 mg/dl, sodium Her toxic encephalopathy improved concurrently with the return to normal of her plasma electrolytes. A neck ultrasound study at that time revealed a nodule. A mass in the region of the left superior parathyroid was resected and was found to be a parathyroid adenoma. She was subsequently discharged, with a normal mental status.
Discussion
There is some evidence that long-term lithium treatment may induce elevations of calcium, magnesium and PTH (Christensson 1976 , Franks et al. 1982 . The mechanism may be resetting the 'calcistat' or the 'set point' (Murray et al. 1972) . Even though this is believed to be innocuous (Franks et al. 1982) , cases of hyperparathyroidism and also parathyroid adenoma have been reported in association with lithium therapy (Table 1) . What is the clinical significance of these findings? Two of our patients manifested severe psychopathology secondary to hyperparathyroidism. In two, operative removal of parathyroid adenoma, and in one discontinuation of lithium, improved the psychopathology as well as the hypercalcaemia. Therefore, it is important clinically to consider parathyroidassociated psychopathology and measure plasma calcium. However, there are no characteristic clinical features to aid the clinician in the diagnosis of this condition, and therefore an element of suspicion and proper investigation are required whenever a change in the course of illness is noted.
Does lithium produce hyperparathyroidism and parathyroid adenoma? Including the 3 reported here, a total of 17 cases have now been reported indicating an association between hyperparathyroidism and lithium administration. However, this could be causal or coincidental, and there is as yet no definite proof that lithium induces parathyroid pathology.
In patients receiving long-term lithium treatment, plasma calcium should be measured initially and then annually with other laboratory investigations. It should also be measured when there is a qualitative change in psychopathology and/or when there is a thyroid abnormality. With significantly elevated plasma calcium, especially when associated with a change in psychopathology, investigations of parathyroid function are indicated and lithium should be withheld until the cause of the hypercalcaemia is established. However, if plasma calcium levels are only slightly elevated without any other abnormal laboratory findings, then lithium may be continued providing calcium levels are monitored closely.
